论文部分内容阅读
MTX已广泛用于治疗较严重的银屑病,但有些用药病人出现肝纤维化。静脉给予MTX后在体内的消除有三相,第一相相当于分布,第二相有赖于肾脏排除,第三相与肠肝循环有关。口服MTX后,其清除有快有慢,是否那些清除较慢者易于产生肝脏纤维化?如果是这样,就有可能通过测定用药后血循环中的MTX来预言哪些病人危险度最高。作者观察了7个发生肝纤维化的银屑病人(经肝活检证实),并以12名无肝纤维化的银屑病人为对
MTX has been widely used to treat more severe psoriasis, but some patients with liver fibrosis. After the intravenous administration of MTX in the body to eliminate three-phase, the first phase is equivalent to distribution, the second phase depends on the exclusion of the kidneys, the third phase and enterohepatic circulation. After oral administration of MTX, its clearance is faster and slower, and is it easier for those with slower clearance to develop liver fibrosis? If so, it is possible to predict which patients are most at risk by measuring MTX in the bloodstream after administration. The authors looked at seven psoriasis patients with liver fibrosis (confirmed by liver biopsy) and 12 of them with psoriasis without liver fibrosis